NCT02172937Unknown1 期
Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Actuarial survival at six months after first DSC infusion
研究概览
简要总结
The purpose of this study is to evaluate safety and efficacy using decidual stromal cell therapy for graft versus host disease after allogeneic hematopoietic stem cell transplantation. The hypothesis to be tested is that the cells are safe to infuse and that they have a positive clinical effect.
详细描述
Patients with GVHD grade 2-4, will receive decidual stromal cells at approximately 1-2x10^6 cells/kg at one or more occasions dependent on clinical response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute graft versus host disease grade 2-
- •Are on calcineurin inhibitor and high dose corticosteroids.
排除标准
- 未提供
结局指标
主要结局
Actuarial survival at six months after first DSC infusion
时间窗: 6 months after inclusion
次要结局
- Incidence of severe infections(Up to one year after inclusion)
- Response at 168 days after onset of graft versus host disease(Up to 168 days after inclusion)
- Side effects(Up to 6 months after inclusion)
- Disease free survival(Up to one year after inclusion)
- Response at 28 days after onset of graft versus host disease(28 days after inclusion)
- Response at 84 days after onset of graft versus host disease(Up to 84 days after inclusion)
研究者
Olle Ringdén
Professor
Karolinska Institutet
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
A Pilot Study Using Placenta Derived Decidual Stromal Cells for Toxicity and Inflammation With Special Focus to the Allogeneic Hematopoietic Cell Transplantation SettingDecidual Stromal CellsStem Cell TransplantationInflammationAcute Lung InjuryNCT02175303Karolinska Institutet25
Unknown
1 期
A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host DiseaseGraft vs Host DiseaseNCT02172924Karolinska Institutet30
已完成
不适用
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory FailureCOVID-19Acute Respiratory Distress SyndromeNCT04451291University Health Network, Toronto19
终止
1 期
Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host DiseaseGraft-Versus-Host DiseaseNCT01522716Karolinska Institutet11
已完成
1 期
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell TransplantCancerNCT00361049Case Comprehensive Cancer Center49